



Promising Novel Urinary Protein Biomarkers for Assessing Drug Induced Acute Kidney Injury: a Review

KEYWORDS

Biomarkers, acute and chronic kidney damage, omics technology, Kim-1, Timp-1, Osteopontin, Cystatin-C.

*Dr. R. Shanmuga Sundaram

Professor and Vice Principal, Department of Pharmacology, J.K.K. Nattraja College of Pharmacy, Salem Main Road, Komarapalayam, Namakkal District, Tamilnadu, India. *Corresponding Author

Abhirama BR

Shree Vidyadhiraja College of Pharmacy, Nemom P.O. Thiruvananthapuram, Kerala, India.

Gowtham L

Department of Pharmacology, Madras Medical College, Chennai, Tamilnadu, India.

Gladys Kalpana

Department of Pharmacology, J.K.K. Nattraja College of Pharmacy, Salem Main Road, Komarapalayam, Namakkal District, Tamilnadu, India.

Pushpa S

Department of Pharmacology, J.K.K. Nattraja College of Pharmacy, Salem Main Road, Komarapalayam, Namakkal District, Tamilnadu, India.

Babitha K Vazhayil

Department of Pharmacology, J.K.K. Nattraja College of Pharmacy, Salem Main Road, Komarapalayam, Namakkal District, Tamilnadu, India.

Sudha M

Department of Pharmacology, J.K.K. Nattraja College of Pharmacy, Salem Main Road, Komarapalayam, Namakkal District, Tamilnadu, India.

Thiyagarajan T

Department of Pharmacology, J.K.K. Nattraja College of Pharmacy, Salem Main Road, Komarapalayam, Namakkal District, Tamilnadu, India.

ABSTRACT Progression of kidney disease from mild to moderate to end stage may be prevented if it is detected at a very early stage. Sensitivity or diagnostic values of all conventional biomarkers are poor, unreliable and their delayed response often delivered false-positive or false-negative results, which finally lead to a late detection of renal damage. Development of omics technology leads to the identification of several urinary protein biomarkers and transcriptional biomarkers which enable earlier detection of kidney injury. Urinary protein biomarkers show good predictive power and have greater benefit, because of easy availability of urine. Several urinary protein biomarkers have been identified and demonstrated superiority in detecting kidney injury than conventional parameters like serum creatinine (SCr), blood urea nitrogen (BUN), etc. These promising experimental biomarkers of kidney damage require further confirmation of their use in routine clinical use.

Conclusion

Nearly for 100 years and still serum creatinine is used as a major determinant of kidney function. RIFLE scheme (risk, injury, failure, loss and end stage renal diseases) and AKIN scheme (acute kidney injury network) are options used for the classification of renal injury. These methods are based on the specific cutoff values of serum creatinine, GFR or urinary output. Different definitions of AKI in the published literature rely on changes in SCr. Kidney disease: improving global outcome (KDIGO) clinical practice guideline for AKI recommends risk assessment for all critically ill patients, acknowledging that risk assessment is difficult. So there is an urgent need for a standard definition which is not based on serum Cr concentration. Markers of damage are better than functional markers.

Difficulty in early or accurate detection of AKI leads to significant problems in patient care and drug development. The data generated during preclinical toxicity testing has to be as detailed and informative as possible as it has been observed that the incidence of patients in intensive care units developing AKI is about 30-50%, but only 7% of new drug candidates fail in the preclinical trials because of toxicity (Devarajan, 2005). This discrepancy may be due to the underestimation of nephrotoxicity in preclinical trials.

Functional genomics and proteomic tools have provided vari-

ous promising novel biomarkers which will be useful for early detection of duration and severity of kidney diseases. But none are currently established enough to replace creatinine as a marker of renal function.

Better biomarkers will help drug developers to take decisions about which products to move forward in testing, doses at which they should be used and designing clinical trials that will provide clear information about product benefit and safety. It also prevents entry of nephrotoxic drugs into the market and facilitates early management of patients who suffer from kidney injury.

Therefore, these promising experimental biomarkers of kidney damage require further confirmation of their use in routine clinical use.

Introduction

Kidney is one of the major organs evoking drug-related toxic responses (Freguson et al., 2008). In the pharmaceutical industry, kidney is one of the routinely assessed organs during preclinical safety evaluations.

Acute Kidney Injury (AKI) remains a common and serious clinical problem which represents an acute decline in renal function, finally leading to structural changes, associated with increased morbidity, mortality, length of hospital stay and costs in both surgical and medical patients. Ischemia, sepsis and toxins are the most common

mmonetiologies in hospitalized patients. Drug-induced kidney disease constitutes an important cause of acute renal failure (ARF) and chronic kidney disease (CKD) in present day clinical practice. Drug-induced ARF accounted for 20% of all ARF in an Indian study (Jha et al., 1995). The incidence of major risk factors of CKD in the world is increasing and, it is expected that this incidence and prevalence, particularly in developing countries, will continue to increase (Najaf et al., 2012). The incidence of end-stage renal disease (ESRD) has also dramatically increasing worldwide (Bommer et al., 2002). Anti-cancer drugs, non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics, angiotensin converting enzyme (ACE) inhibitors, contrast agents and heavy metals are major culprit drugs contributory to kidney damage (Jha et al., 1995).

Standard parameters in preclinical and clinical studies as well as in routine clinical care for the detection and monitoring of renal function are serum creatinine (SCr) and blood urea nitrogen (BUN). Some other tests that measure abnormal kidney functions include lowered (<60%) glomerular filtration rate (GFR), proteinuria, hematuria, high blood pressure, detection of urinary components like electrolytes, enzymes and other waste products. It is often associated with frequent or painful urination, swelling of hands or in feet and puffiness around the eyes etc.

Drug-induced renal toxicity on animals system can be directly observed and characterized through histopathological observation, is currently considered as gold standard in preclinical studies. However, it is difficult to identify the time at which kidney damage occurs. It does not give any detailed information of non-histopathology associated type of kidney disturbances.

However, sensitivity or diagnostic values of all of these parameters are poor, unreliable and their delayed response often deliver false-positive or false-negative results which finally lead to late detection of renal damage for which dialysis is the only option for treatment. All of these symptoms are not specific for kidney damage but are also reported for other organ damage or diseases. A reduction of renal functionality occurs only after two thirds of renal biomass has been injured (Rached et al., 2008).

Development of micro technology lead to the identification of several urinary protein biomarkers and transcriptional biomarkers which enable earlier detection of kidney injury and also gives information about the area of nephron damage or the underlying mechanism. Novel kidney injury biomarkers in both serum and urine have been demonstrated superiorly in detecting kidney injury before changes in conventional parameters like serum creatinine or BUN.

Urinary protein biomarkers have great benefit to feasibility of urine sample and lack of sample preparation and many showing good predictive power. Enhanced sample preparation effort and limitation in tissue availability limits the routine use of transcriptional biomarker compared to urinary proteins biomarkers. Several urinary protein biomarkers of nephrotoxicity like Kidney Injury Molecule (Kim-1), Clusterin, Neutrophil Gelatinase associated Lipocalin or Lipocalin-2 (NGAL/Lcn-2), Tissue inhibitor of Metalloproteinases-1 (Timp-1), Osteopontin (OPN), Interleukin-18 (IL-18), Fatty Acid Binding Protein-Liver Type (L-FABP), Vanin, Trefoil factor-3 (TFF-3), etc., have been identified in kidney tissues, serum and urine by using ELISA, immunohistochemistry and quantitative real time PCR methods.

This review is aimed at shedding light on some of the most promising biomarkers currently under investigation, for identifying toxin-mediated acute kidney injury.

Recent reports on the most promising urinary protein biomarkers

1. Kidney Injury Molecule-1 (KIM-1)

Kim-1 is a type-I transmembrane glycoprotein with an immu-

noglobulin-like domain consisting of six unusual cysteine- and a long mucin-like domain in extracellular region, localized to the apical membrane of exclusively surviving proximal tubule epithelial cells after injury (Vaidya et al., 2008). It internalizes apoptotic bodies and cell debris facilitating, remodeling and regeneration of tubule epithelium and thus preventing tubule obstruction in response to injury. It is expressed at low level in normal kidney tissue but dramatically upregulated and easily detected in the urine upon nephrotoxicity.

Kim-1 has been considered as a non-invasive biomarker for human renal proximal tubule damage (Ichimura et al., 1998). Hoffmann et al., 2010 analyzed the level of Kim-1, Lipocalin-2, Clusterin and Timp-1 in the kidney and confirmed that Kim-1 and Clusterin are early, sensitive and non-invasive markers of renal injury, as the markers reflected changes in gene/protein expression and histopathological alterations, in absence of functional changes. Previous studies in rats and in patients with AKI demonstrated, significantly higher sensitivity and specificity of urinary Kim-1 and Clusterin, as markers of renal injury than traditional clinical chemistry parameters (Ettefali et al., 1993; Han et al., 2008; Horstrup et al., 2002; Zhou et al., 2008; Vaidya et al., 2008). Kim-1 is not detected in normal tissue or urine, but highly expressed in proximal tubule epithelial cells following toxic injury (Vaidya et al., 2006). Administration of Ochratoxin A to rats resulted in a dose-time-dependent increase in the gene expression of Kim-1, Lipocalin-2, Timp-1, OPN and Clusterin. Induction of Kim-1 gene expression is the earliest response of the kidney to any significant increase in gene expression has been seen in invitro studies (Eva Rached et al., 2008). Urinary Kim-1 levels were significantly elevated within 12h after aristolochic acid administration, with significant increase of BUN levels, only on day 5, but no changes in urinary NAG and total protein were detected throughout the study (Sabbiseti et al., 2012). However, urinary Kim-1 is reported to be increased after the peak of urinary NAG and NGAL in patients with AKI after cardiac surgery (Han et al., 2009).

2. Lipocalin-2/Neutrophil Gelatinase Associated Lipocalin/ (Lcn-2/NGAL)

Lipocalin are small proteins that are secreted by cells to bind things and carry them back, most important lipocalins are siderophores. This family includes several proteins such as α 1-microglobulin, retinol binding protein-4, prostaglandin synthase and nitrothiophorins, which are specialized in binding and transporting small hydrophobic molecules. NGAL, also known as human neutrophil lipocalin, lipocalin-2, and siderocalin belong to well defined superfamily of proteins called lipocalins. NGAL is a protein that binds to gelatinase in particular neutrophil granulocytes and is upregulated during inflammation or tumorigenesis (Nielson et al., 1996) and also might be readily detected in urine. NGAL may be produced in many cells including kidney tubule. NGAL level predicts the future appearance of AKI after treatment that/which adversely affects kidney. Recent evidence also suggests that it may be involved in pathophysiological process of chronic renal diseases such as polycystic kidney disease and glomerulonephritis and highly expressed in many other conditions, like infection or inflammation, including appendicitis, inflammatory bowel disease or urinary tract infections, but in clinical practice, the interest is focused on AKI. For all these reasons, NGAL may become one of the most promising next-generation biomarkers in clinical nephrology.

NGAL was easily detected in urine of mouse with cisplatin-induced nephrotoxicity preceding the appearance of NAG and β_2 -microglobulin, suggesting as an early, non-invasive biomarker for ischemia and nephrotoxic renal injury (Mishra et al., 2003). In a previous study, rats were administered with gentamicin and urinary Lcn2 was found to be performed better than kim-1 (Seiber et al., 2009). NGAL/lipocalin-2 has been rapidly increased and secreted into urine in a range of preclinical and clinical studies on AKI (Bennett et al., 2008; Nikolaset al., 2008).

Plasma and urine NGAL have emerged as sensitive, specific and highly predictive early biomarkers of AKI after cardiac surgery in

children, since NGAL concentration increased within 2–6 h in patients who subsequently developed AKI after surgery (Waikare et al., 2009). However, it has been demonstrated that urinary concentrations of Lcn2 also is increased in liver fibrosis induced by carbontetrachloride (Smyth et al., 2008), and elevated in patients with hpneumonia (Chan et al., 2009) and inflammatory bowel disease (Oikonomou et al., 2011). Hence it is suggested that it may not be specific for kidney injury but also occur in response to systemic inflammation or tissue damage at other sites or organs.

3. Clusterin

Clusterin is a disulphide-linked heterodimeric glycoprotein consisting of α and β subunits (Jones and Jomary, 2000; Kujiraoka et al., 2004), present in the cytoplasm of proximal convoluted tubule or at the end of distal convoluted tubule (DCT) including connecting tubule in the kidney cortex. Clusterin, an apolipoprotein when secreted, protects cells against apoptosis and cytotoxicity by complement and associates with membran recycling, lipid transport, tissue remodeling, spermaturation, etc (July et al., 2002). It can be used as a potential marker of nephrotoxicity, since it is upregulated and detected in the urine of patients with AKI. It has been confirmed that the depletion of clusterin worsens glomerulonephritis (Kharasch et al., 2006).

Increased expression of clusterin was found in tubules showing signs of cell death and regeneration, indicating its role in tissue remodeling after damage (Rosenberger et al., 1995). Clusterin has been implicated in apoptosis and growth control, cell adhesion and tissue remodeling and significantly upregulated in response to cellular stress (Shannan et al., 2006). Reduction of inducible expression of clusterin results in an increase in renal tubular epithelial cell apoptosis in the cultures and renders mice more susceptible to ischaemic-reperfusion injury, showing a protective role of clusterin in kidney injury (Wenjun Zhou et al., 2010). Expression of clusterin mRNA was significantly increased within 6 h in rat unilateral ureteral obstruction model and suggested that detection of clusterin mRNA and clusterin- β in the kidney or clusterin- α in the urine may be useful for predicting nephrotoxicity (Ishikawa et al., 2007). Clusterin has significantly increased in patients with bladder cancer raising the concern that the presence of clusterin may not be linked only to kidney toxicity (Stejskal and Fiala, 2006).

4. Interleukin-18 (IL-18)

IL-18 is a widely expressed pro-inflammatory cytokine, formerly known as interferon- γ -inducing factor, produced by renal tubular cells and by macrophages. IL-18 induces interferon- γ production in T cells and natural killer cells and has an active role in apoptosis, ischemia, infection, malignancy and autoimmune condition (Melnikov et al., 2001).

John et al., 2013, measured the concentration of IL-18 in urine samples of 95 patients with AKI after cardiac surgery and found IL-18 was the best predictor, in addition to L-FABP, NGAL and KIM-1, which were also good predictors. Liu et al., 2013 found IL-18 as a useful biomarker of AKI with moderate predictive value across all clinical settings. In a cross-sectional study, urine IL-18 levels were markedly elevated in patients with established AKI, but not in subjects with UTI, CKD and nephrotic syndrome (Parikh et al., 2004). Urinary IL-18 was significantly upregulated in patients with acute respiratory distress syndrome who developed AKI (Parikh et al., 2005). Urinary IL-18 level was significantly elevated within 6 h in children undergoing cardiopulmonary bypass (CPB) who developed AKI (Parikh et al., 2006). IL-18 is a predictive biomarker in kidney transplantation (Parikh et al., 2006). Overall, IL-18 appears to be more specific to AKI and has been anticipated as a possible early marker.

5. Vanin-1

Vanin-1 is an epithelial ectoenzyme with pantetheinase activity, which catalyzes the conversion of pantethein to pantothenic acid and cysteamine. Lack of cysteamine is associated with the hunched-glutamylcysteinesynthetase activity leading to the elevation of endogenous glutathione in tissues which protect tissue against the degenerating effects of oxidized damage by scavenging free radicals (Meister and Anderson, 1983). High-

er serum and urinary concentrations of Vanin-1 were observed in ethylene glycol treated groups compared to control group, suggesting it as a useful and rapid biomarker for renal tubular injury (Hosohata et al., 2011).

A recent study has been conducted to determine whether increase in urinary vanin is detected before the elevations of serum creatinine, urinary NAG, Kim-1, and NGAL in animal models induced nephrotoxicity by cisplatin and gentamicin. Urinary vanin-1 was detected earlier than any other biomarkers after the administration of higher doses of both drugs. This result suggested that, compared with urinary Kim-1 and NGAL, urinary vanin-1 is an earlier and equally sensitive biomarker for drug-induced AKI (Keiko Hosohata et al., 2012). Urinary Vanin-1 was increased in patients with diabetic nephropathy (Fugmann et al., 2011) and protein levels of renal vanin-1 was increased in rats with streptozotocin-induced diabetic nephropathy. Therefore, it is anticipated that urinary vanin-1 is a potential biomarker for early detection of AKI.

6. Trefoil factor 3 (TFF3)

Trefoil factors are multifunctional peptides, mainly expressed in alimentary canal and protect it from the degradative effect of HCl, by stimulating goblet cell mucus synthesis and mucin. Downregulation of trefoil factor 3 may contribute to increased age-related tissue damage to the kidney. TFF3 may play a role in regeneration and in ongoing repair of kidney damage (Astora et al., 2011).

Urinary TFF3 and albumin enabled more sensitive markers for diagnosis of acute renal tubular injury than traditional markers (Yu et al., 2010). A case control study that was performed over 8.6 years found that higher urinary TFF3 were associated with CKD, may be a useful marker in future studies (Astora et al., 2011). Expression of TFF3 in vivo is correlated with inflammation of gastrointestinal tract, and a variety of solid cancers (Khouri et al., 2005). The study reports indicate that it may not be a specific indicator for acute kidney toxicity.

7. Insulin-like growth factor binding protein-7 (IGFBP7)

IGFBP7 involved in G1 cell cycle arrest during early phase of cell injury and may prevent the cell division with damaged DNA, until DNA damage is repaired (Rodier et al., 2007; Boonstra et al., 2004).

Previous study investigated the concentration of urinary IGFBP7 and Timp-1 in 50 patients undergoing cardiac surgery and results indicated that both served as sensitive and specific biomarkers to predict AKI early, after cardiac surgery and to predict renal recovery. AUC level was significantly higher for IGFBP7 and Timp-1, i.e., superior to other biomarkers like Kim-1, NGAL, cystatin C, IL-18 to predict AKI (Mishra et al., 2003; Koynere et al., 2008; Han et al., 2002).

8. Tissue inhibitor of metalloproteinase-1 (Timp-1)

Timp-1 is an endogenous, specific inhibitor of matrix metalloproteinases (MMPs) by forming high affinity complexes and thereby blocking binding of MMPs to the substrate. MMPs, belonged to a family of proteolytic enzymes that degrade various types of extracellular matrix components (ECM). Timp-1 promotes renal fibrosis through inhibition of matrix metalloproteinase and accumulation of collagen. Downregulation of MMPs and upregulation of TIMPs lead to accumulation of ECM proteins and progression of CRF, which are characterized by tubulointerstitial fibrosis and glomerulosclerosis (Lenz et al., 2000). It also involved in G1 cell cycle arrest. Previous studies reported increased urinary excretion of Timp-1 in patients with renal disease.

Previous study demonstrated that the protective role of MMP-9 in CRF was by degrading ECM through the suppression of Timp-1 and the proinflammatory response (Leiwanget al., 2013). Enhanced urinary excretion of Timp-1 was seen in high dose animals (Hoffman et al., 2010) but the overall performance of Timp-1 as an early indicator of proximal tubular injury was poor, compared to Kim-1 and clusterin. Elevated levels of Timp-1 have been observed in models of kidney injury and in urine of patients with renal disease as compared to healthy controls (Wasilewska and Zoch-Zwierz, 2008). Recent evidence suggests that Timp-1 increases granulocyte during infla-

mation (Chormek et al., 2004). TIMP-1 and clusterin were found to be less sensitive than Kim-1 and lipocalin (Maxetal., 2009).

9. Liver-type Fatty acid Binding Protein (L-FABP)

L-FABP is a small cytoplasmic protein abundantly expressed mainly in proximal tubule of kidney and also in tissues with active fatty acid metabolism. Primary function of this protein is the facilitation of long chain fatty acid transport.

Increased urinary expressions have been described in animal models of AKI (Noiri et al., 2009; Yamamoto et al., 2007; Negishi et al., 2009). In hospitalized patients with established AKI, the AUC of urinary L-FABP for prediction of AKI was 0.97, which is higher in patients with poor outcome (Ferguson et al., 2010). In patients with septic shock and AKI, urinary L-FABP levels were significantly higher (Doi et al., 2010) and also increased in CKD (Kamijo et al., 2006). Urinary L-type fatty acid binding protein was shown to increase within 2 h of cisplatin administration and correlated with histological injury score than BUN (Negishi et al., 2009), indicating L-FABP as a promising and sensitive biomarker than Kim-1.

10. Osteopontin (OPN)

Osteopontin, a bone phosphoprotein, is a multifunctional protein secreted by a variety of cell types and is involved in diverse biological processes including inflammation, leukocyte recruitment, wound healing, and cell survival and also in biological calcification. It is also known as sialoprotein I, secreted phosphoprotein I, uropontin and early T-lymphocyte activation-1 (Eta-1) (Oldberg et al., 1986; Nomura et al., 1988; Patarca et al., 1989; Shiraga et al., 1992). OPN is synthesized with in kidney and is present in human urine at levels that can effectively inhibit CaOx crystallization (Min et al., 1998; Aspin et al., 1998).

It is expressed most highly in epithelial tissue and bone, and can be detected at a high level in human urine when the kidney is significantly damaged by gentamicin, cisplatin, cyclosporin, sevoflurane, angiotensin II-induced tubulointerstitial nephritis, and puromycin-induced glomerulonephritis (Alchiet al., 2005). Studies demonstrated that increased urinary levels of OPN, in children with steroid-resistant nephrotic syndrome as well as in mice suffering from focal segmental glomerulosclerosis, indicated as a promising kidney marker (Lorenzen et al., 2008; Shu et al., 2007).

11. Renal papillary antigen (RPA-1)

RPA-1 is a collecting duct-specific protein of high molecular weight glycoprotein, and the actual epitope recognize by the RPA-1 antibody is likely to be carbohydrate in nature, forming part of an N-linked glycoprotein.

Gentamicin and chromium treated rat sex exhibited increased immunoreactivity of RPA-1, RPA-2, Kim-1 largely in the S1/S2 segments and to a lesser extent in the S3 segments of the proximal tubule of kidney, whereas mercury (Hg) treated rats showed increased immunoreactivity of Kim-1, RPA-1, RPA-2 in the S3 segments. These proteins were more abundant in injured, necrotic, and apoptotic cells of S1/S2 and S3 segments than in the normal healthy rats (Jun Zhan et al., 2008).

12. Hepatocyte growth factor (HGF)

Hepatocyte growth factor, is a pleiotrophic factor originally isolated as a potent mitogen for hepatocytes and plays an important role in tissue repair and regeneration after injury. Expression of both HGF and its c-met receptor genes is rapidly upregulated after AKI.

Administration of exogenous HGF not only promotes renal tubular repair after injury but also functions as a cytoprotective agent by protecting tubular epithelial cells against both apoptotic and necrotic death (Chun Sun Det al., 2001). Visha et al., 2008 evaluated the diagnostic performance of 9 urinary protein biomarkers of AKI including Kim-1, IL-18, HGF, Cystatin C, NGAL, NAG, VEGF, c hemokine interferon-inducible protein (IP-10) and total protein in a cross-sectional comparison of 204 patients and confirmed that KIM-1, NGAL, HGF and total protein were the four best performer

individually and in combinations.

13. Cystatin-C

Cystatin-C is a non-glycosylated extracellular cysteine protease inhibitor and a potent inhibitor of lysosomal proteinases, and mainly used as a biomarker of kidney function. Cystatin-C is found in CSF and urine of patients with renal failure. If kidney function and GFR declines, the blood level of Cystatin-C rises. Cystatin-C is less dependent on age, sex, race and muscle mass compared to creatinine.

Kim-1, Cystatin-C, TIMP-1, and osteopontin may serve as promising non-invasive urinary biomarkers for earlier detection and monitoring of renal injury compared to other biomarkers like beta-2-microglobulin, α -GST, VEGF, calbindin, clusterin, NGAL, OPN, BUN and SCr in kidney toxicity induced rat models (Mihye et al., 2012). Cystatin levels have been reported to be altered in patients with cancer (Kosetal., 1998), thyroid dysfunction (Fricker M et al., 2003), HIV infection (Odden et al., 2007), cardiovascular diseases, and brain disorders like Alzheimer's disease.

14. Type IV collagen

Type IV collagen, a main component of the basement membrane, increases in the urine following damage of the glomerulus. Because it is too large to pass through the outer membrane of the glomerulus, its concentration in the urine is a sensitive indicator for glomerular changes in the structure of the extracellular matrix and thus an important anti-biomarker of nephrotoxicity (Donovan et al., 1994)

In addition to the aforementioned urinary protein biomarkers, various cytokines like interferon, tumour necrosis factor, colony stimulating factor and several growth factors act as mediators of inflammation and immune responses and as a biomarker of nephrotoxicity, because they are involved in tubular damage and repair.

Future Prospects

Future studies are required

- i). To validate the sensitivity and specificity of these markers in clinical samples from large cohorts and in multiple clinical situations,
- ii). To understand the performance of these biomarkers in other types of renal injury,
- iii). To elucidate why certain nephron segments are affected by certain toxicants and not by others and this may help to identify mechanism of toxic action and aid the search for site-specific biomarkers.
- iv). To date only limited data are available regarding gender difference in drug induced renal injury.

Research studies focusing only on Kim-1, would be wrong as it indicates the renal damage only on S3 segments (Rosen and Hayden, 2003). Recent reports also indicate that other biomarkers like IL-18, IGFBP and Vanin are more sensitive than Kim-1.

Conclusion

Nearly for 100 years and still serum creatinine is used as a major determinant of kidney function. RIFLE scheme (risk, injury, failure, loss and end stage renal diseases) and AKIN scheme (acute kidney injury network) are options used for the classification of renal injury. These methods are based on the specific cut-off values of serum creatinine, GFR or urinary output. Different definitions of AKI in the published literatures rely on changes in SCr. Kidney disease: improving global outcome (KDIGO) clinical practice guideline for AKI recommends risk assessment for all critically ill patients, acknowledging that risk assessment is difficult. So there is an urgent need for a standard definition which is not based on serum Cr concentration. Markers of damage are better than functional markers.

Difficulty in early or accurate detection of AKI leads to significant problems in patient care and drug development. The data generated during preclinical toxicity testing has to be as detailed and informative as possible as it has been ob-

served that the incidence of patients in intensive care units developing AKI is about 30-50%, but only 7% of new drug candidates fail in the preclinical trials because of toxicity (Devarajan, 2005). This discrepancy may be due to the underestimation of nephrotoxicity in preclinical trials.

Functional genomics and proteomic tools have provided various promising novel biomarkers which will be useful for early detection of duration and severity of kidney diseases. But none are currently established enough to replace creatinine as a marker of renal function.

Better biomarkers will help drug developers to take decisions about which products to move forward in testing, doses at which they should be used and designing clinical trials that will provide clear information about product benefit and safety. It also prevents entry of nephrotoxic drugs into the market and facilitates early management of patients who suffer from kidney injury.

Therefore, these promising experimental biomarkers of kidney damage require further confirmation of its use in routine clinical use.

